Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017
Summary
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Tissue factor pathway inhibitor (TFPI) is a single-chain polypeptide. It inhibits factor Xa directly and in a Xa-dependent way, inhibits VIIa/tissue factor activity. It has an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hematological Disorders which include indications Hemophilia A, Hemophilia B and Hemophilia.
The latest report Tissue Factor Pathway Inhibitor - Pipeline Review, H2 2017, outlays comprehensive information on the Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
- The report reviews Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Summary
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Tissue factor pathway inhibitor (TFPI) is a single-chain polypeptide. It inhibits factor Xa directly and in a Xa-dependent way, inhibits VIIa/tissue factor activity. It has an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hematological Disorders which include indications Hemophilia A, Hemophilia B and Hemophilia.
The latest report Tissue Factor Pathway Inhibitor - Pipeline Review, H2 2017, outlays comprehensive information on the Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
- The report reviews Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
TABLE OF CONTENTS
Introduction
Global Markets Direct Report Coverage
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Overview
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Companies Involved in Therapeutics Development
Bayer AG
Green Cross Corp
Novo Nordisk A/S
Pfizer Inc
Shire Plc
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Drug Profiles
BAY-1093884 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
concizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-1113A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06741086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit TFPI for Hemophilia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Dormant Products
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Discontinued Products
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Product Development Milestones
Featured News & Press Releases
Nov 30, 2015: New Data from Bayers Portfolio in Hematology to be Presented at ASH 2015
Oct 30, 2015: MorphoSys Announces Clinical Milestone in Hemophilia Program with Bayer HealthCare
Feb 06, 2007: Jerini Expands Collaboration With Baxter To Develop Non-intraveneous Hemophilia Therapy
May 22, 2006: Baxter And Jerini Find Candidates For Development In Hemophilia
May 18, 2006: Baxter And Jerini Advance Program To Develop Non-Intravenous Hemophilia Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Bayer AG, H2 2017
Pipeline by Green Cross Corp, H2 2017
Pipeline by Novo Nordisk A/S, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Shire Plc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
List Of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
RELATED REPORTS
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021
DelveInsights, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight, 2021, report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It
View ReportMucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) - Drugs in Development, 2021
Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) - Drugs in Development, 2021Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
